AbbVie director granted stock equivalent units

AbbVie Inc. director Edward J. Rapp reported receiving a grant of stock equivalent units as part of his board compensation.

Rhea-AI Filing Summary

AbbVie Inc. director Edward J. Rapp reported receiving a grant of stock equivalent units as part of his board compensation. He acquired 134 stock equivalent units on June 30, 2026 at a reference value of $251.64 per unit, each tied to AbbVie common stock. Following this grant, his reported balance increased to 29,236 stock equivalent units, which earn the same return as if the fees were invested directly in AbbVie stock and include units added through a dividend reinvestment feature. These units are credited to a director grantor trust and are scheduled to be distributed over a period equal to his years of board service, generally beginning at the later of age 65 or retirement from the board.

Insider Trade Summary

Grant/Award: 134 shares

Grant/Award 1 txn

Insider RAPP EDWARD J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Equivalent Units	134	$251.64	$34K

Holdings After Transaction: Stock Equivalent Units — 29,236 contracts (Direct)

Footnotes (2)

1. F1. Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
2. F2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Key Figures

Stock equivalent units granted: 134 units Reference value per unit: $251.64 per unit Total stock equivalent units after grant: 29,236 units +1 more

4 metrics

Stock equivalent units granted 134 units Grant on June 30, 2026 to director Edward J. Rapp

Reference value per unit $251.64 per unit Stock equivalent units tied to AbbVie common stock

Total stock equivalent units after grant 29,236 units Balance following June 30, 2026 transaction

Underlying common stock 134 shares Underlying AbbVie common stock per new stock equivalent units

Key Terms

Stock Equivalent Units, grantor trust, dividend reinvestment feature, director fees

4 terms

Stock Equivalent Units financial

"Director fees credited to a stock equivalent unit account under the director's grantor trust"

Stock equivalent units are financial claims or instruments that are treated as if they were actual shares for purposes like calculating ownership, dilution, and earnings per share. Think of them as promises or placeholders for future slices of company pie—options, restricted units, or convertible securities—that don’t yet sit on the table but will reduce each existing slice when converted. Investors track them because they change how much of a company each share really represents and can affect valuation and voting power.

grantor trust financial

"Director fees credited to a stock equivalent unit account under the director's grantor trust"

A grantor trust is a legal arrangement where the person who puts assets into the trust keeps enough control or rights that, for tax and legal purposes, those assets are treated as still belonging to that person. For investors, that matters because income, gains and losses generated by the trust typically flow through to the grantor (or directly to investors) for tax reporting and distributions, affecting after-tax returns and cash flow predictability — think of it like a mailbox that forwards all the mail back to the sender rather than holding it inside.

dividend reinvestment feature financial

"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature"

director fees financial

"Director fees credited to a stock equivalent unit account under the director's grantor trust"

FAQ

What insider transaction did AbbVie (ABBV) director Edward J. Rapp report?

Edward J. Rapp reported an acquisition of 134 stock equivalent units as part of his director compensation. These units are linked to AbbVie common stock and increase his total stock equivalent unit balance credited under the company’s director compensation programs.

How many AbbVie (ABBV) stock equivalent units does Edward J. Rapp now hold?

After this grant, Edward J. Rapp’s reported balance is 29,236 stock equivalent units. This figure includes units from director fees and additional units acquired under a dividend reinvestment feature tied to AbbVie’s stock performance over time.

What are AbbVie (ABBV) stock equivalent units for directors and how do they work?

AbbVie stock equivalent units are bookkeeping entries that mirror AbbVie common stock returns. Director fees are credited into a stock equivalent unit account, which earns the same return as AbbVie stock and can grow further through a dividend reinvestment feature over time.

When will Edward J. Rapp receive his AbbVie (ABBV) stock equivalent units?

The stock equivalent units are scheduled for distribution over a period equal to Edward J. Rapp’s years of board service. Distributions generally begin at the later of his reaching age 65 or his retirement from AbbVie’s board of directors.

How was the value of AbbVie (ABBV) stock equivalent units determined in this Form 4?

The Form 4 lists a reference value of $251.64 per stock equivalent unit for the June 30, 2026 grant. Each unit corresponds to AbbVie common stock and earns the same return as if the underlying director fees were invested directly in AbbVie shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAPP EDWARD J

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	$251.64	06/30/2026		A		134		(1)	(1)	Common Stock	134	$251.64	29,236(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ T.O. Odutayo, Attorney-in-Fact for Edward J. Rapp	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)